

John E Bowen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8900043/publications.pdf>

Version: 2024-02-01

25
papers

10,986
citations

279701

23
h-index

610775

24
g-index

49
all docs

49
docs citations

49
times ranked

12256
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. <i>Cell</i> , 2022, 185, 872-880.e3.	13.5	165
2	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. <i>Science</i> , 2022, 375, 449-454.	6.0	108
3	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. <i>Nature</i> , 2022, 603, 706-714.	13.7	756
4	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	2.1	48
5	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 2022, 602, 664-670.	13.7	917
6	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. <i>Science</i> , 2022, 375, 864-868.	6.0	394
7	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. <i>Science Translational Medicine</i> , 2022, 14, eabn1252.	5.8	68
8	Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants. <i>Nature Biotechnology</i> , 2022, 40, 1336-1340.	9.4	23
9	ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. <i>Science</i> , 2022, 377, 735-742.	6.0	85
10	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. <i>Nature</i> , 2021, 593, 136-141.	13.7	648
11	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021, 184, 2332-2347.e16.	13.5	784
12	Structural basis for broad coronavirus neutralization. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 478-486.	3.6	152
13	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. <i>Nature</i> , 2021, 595, 707-712.	13.7	363
14	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654.	6.0	385
15	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021, 597, 103-108.	13.7	220
16	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , 2021, 597, 97-102.	13.7	385
17	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. <i>Nature</i> , 2021, 598, 342-347.	13.7	230
18	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	13.5	131

#	ARTICLE	IF	CITATIONS
19	Broad betacoronavirus neutralization by a stem helix-specific human antibody. <i>Science</i> , 2021, 373, 1109-1116.	6.0	262
20	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , 2021, 374, 1621-1626.	6.0	232
21	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <i>Cell</i> , 2020, 183, 1024-1042.e21.	13.5	1,195
22	Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 942-949.	3.6	153
23	Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. <i>Cell</i> , 2020, 182, 1295-1310.e20.	13.5	1,726
24	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020, 370, 950-957.	6.0	504
25	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 0, , .	13.7	101